Literature DB >> 7954522

The immunobiological effects of interleukin-2 in vivo.

R A Janssen1, N H Mulder, T H The, L de Leij.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7954522     DOI： 10.1007/BF01525983

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN： 0340-7004            Impact factor:   6.968


× No keyword cloud information.
  129 in total

1.  Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.

Authors:  J W Clark; J W Smith; R G Steis; W J Urba; E Crum; R Miller; J McKnight; J Beman; H C Stevenson; S Creekmore
Journal:  Cancer Res       Date:  1990-11-15       Impact factor: 12.701

2.  Patterns of human tumor-infiltrating lymphocytes in 120 human cancers.

Authors:  C M Balch; L B Riley; Y J Bae; M A Salmeron; C D Platsoucas; A von Eschenbach; K Itoh
Journal:  Arch Surg       Date:  1990-02

3.  Human memory T cells express intercellular adhesion molecule-1 which can be increased by interleukin 2 and interferon-gamma.

Authors:  A M Buckle; N Hogg
Journal:  Eur J Immunol       Date:  1990-02       Impact factor: 5.532

4.  IL-2-based immunotherapy alters circulating neutrophil Fc receptor expression and chemotaxis.

Authors:  D Jablons; E Bolton; S Mertins; M Rubin; P Pizzo; S A Rosenberg; M T Lotze
Journal:  J Immunol       Date:  1990-05-01       Impact factor: 5.422

5.  Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis.

Authors:  D T Sleijfer; R A Janssen; J Buter; E G de Vries; P H Willemse; N H Mulder
Journal:  J Clin Oncol       Date:  1992-07       Impact factor: 44.544

6.  The IL-2 receptor beta subunit is absolutely required for mediating the IL-2-induced activation of NK activity and proliferative activity of human large granular lymphocytes.

Authors:  H Umehara; E T Bloom
Journal:  Immunology       Date:  1990-05       Impact factor: 7.397

7.  Phase I evaluation of combination therapy with interleukin 2 and gamma-interferon.

Authors:  L M Weiner; K Padavic-Shaller; J Kitson; P Watts; R L Krigel; S Litwin
Journal:  Cancer Res       Date:  1991-08-01       Impact factor: 12.701

8.  Peripheral blood lymphocyte number and phenotype prior to therapy correlate with response in subcutaneously applied rIL-2 therapy of renal cell carcinoma.

Authors:  R A Janssen; D T Sleijfer; A A Heijn; N H Mulder; T H The; L de Leij
Journal:  Br J Cancer       Date:  1992-12       Impact factor: 7.640

9.  CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help.

Authors:  F A Harding; J P Allison
Journal:  J Exp Med       Date:  1993-06-01       Impact factor: 14.307

10.  Induction of soluble tumour necrosis factor receptors during treatment with interleukin-2.

Authors:  D W Miles; D Aderka; H Engelmann; D Wallach; F R Balkwill
Journal:  Br J Cancer       Date:  1992-12       Impact factor: 7.640
View more
  6 in total

1.  Interleukin-2 affects steroidogenesis and numbers of bovine ovarian granulosa cells but not thecal cellsin vitro.

Authors:  C A Rajagopala Raja; L J Spicer; R E Stewart
Journal:  Endocrine       Date:  1995-12       Impact factor: 3.633

2.  Immune reactions induced by interleukin-2 transfected colorectal cancer cells in vitro: predominant induction of lymphokine-activated killer cells.

Authors:  M Lindauer; H K Schackert; J Gebert; W Rudy; A Habicht; M Siebels; S C Meuer; U Moebius
Journal:  J Mol Med (Berl)       Date:  1996-01       Impact factor: 4.599

3.  Synergistic antitumour effects of chemo-immunotherapy with an oxazaphosphorine drug and IL-2-secreting cells in a mouse colon cancer model.

Authors:  H Kusnierczyk; E Pajtasz-Piasecka; C Radzikowski
Journal:  Med Oncol       Date:  1999-12       Impact factor: 3.738

4.  Treatment of metastatic renal cell carcinoma with subcutaneous interleukin 2: evidence for non-renal clearance of cytokines.

Authors:  R E Banks; M A Forbes; S Hallam; A Jenkins; M Wadhwa; P Dilger; A Meager; R Thorpe; C J Bowmer; J K Joffe; P Patel; P W Johnson; P J Selby
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

5.  Immunomodulatory effects of intravenous BIS-1 F(ab')2 administration in renal cell cancer patients.

Authors:  R A Janssen; B J Kroesen; J Buter; G Mesander; D T Sleijfer; T H The; N H Mulder; L de Leij
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

6.  Local therapy of cancer with free IL-2.

Authors:  Willem Den Otter; John J L Jacobs; Jan J Battermann; Gerrit Jan Hordijk; Zachary Krastev; Ekaterina V Moiseeva; Rachel J E Stewart; Paul G P M Ziekman; Jan Willem Koten
Journal:  Cancer Immunol Immunother       Date:  2008-07       Impact factor: 6.968
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.